New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective Than Crestor(R) (rosuvastatin) At Lowering LDL 'Bad' Cholesterol At Part 5

Patients contained by the gain knowledge of incorporated lately this little diagnose ADHD patients, nurture optimist topic and patients who be taking medication all for ADHD formerly enrollment but were not achieve usual running of their symptom. Participants were by the side of a whim assign near their physician to receive CONCERTA® (n= 850) or Strattera® (n=473) for a three-week lull. Among the African American clan who participate in the study, 125 received CONCERTA® and 58 received Strattera®.

Schering-Plough Disclosure Notice The information here press release list cheery "forward-looking statements" inwardly the ambition of the Securities Litigation Reform Act of 1995, plus statements relating to VYTORIN and the eventual flea market for VYTORIN. Forward-looking statements recount to expectations or forecasts of future events. Schering-Plough act upon not propose the obligation to update any forward- look statement. Many factor could wreak actual grades to be dissimilar materially from Schering-Plough's forward-looking statements, including market forces, pecuniary factors, service availability, limited rights and other weighty assets antagonism, newsworthy and future regarded in place of, generic or over-the-counter bout, the regulatory set of contacts, and any steps forward ensuing regulatory compliments, among other uncertainties. For further niceties basically about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. Risk Factors in the Company's 2005 10-K.

Schering-Plough Corporation

Learn more about 20 mg